ORALTAG (iohexol) by R-Pharm US is x-ray contrast activity [moa]. First approved in 2015.
Drug data last refreshed 11h ago · AI intelligence enriched 14h ago
ORALTAG (iohexol) is an oral X-ray contrast agent used to visualize the gastrointestinal tract during radiographic imaging procedures. It functions as a radio-opaque medium that enhances visualization of internal structures on X-ray imaging. Patients requiring diagnostic imaging of the GI tract receive this solution orally prior to imaging.
Established peak-lifecycle product with modest competitive pressure (30%), suggesting stable but mature market positioning with limited growth headroom.
X-Ray Contrast Activity
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Relative Bioavailability of CE-Iohexol (Captisol-enabled™ Iohexol) Injection and Omnipaque™ Injection
A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants
Oral Iohexol for Fecal/Fluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles
A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects
Worked on ORALTAG at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
ORALTAG presents a stable career opportunity in a mature diagnostic imaging franchise with limited growth acceleration but predictable revenue streams. Roles on this product emphasize market maintenance, healthcare provider relationships, and operational excellence rather than launch innovation.